ASCO 2024: Updates in Multiple Myeloma : Episode 1
Opinion
Video
Unmet Needs in Multiple Myeloma Ahead of ASCO 2024
Alfred L. Garfall, MD, opens a discussion underscoring the unmet needs in multiple myeloma.
Video content above is prompted by the following:
- Coming into ASCO 2024, what did you consider to be the largest unmet needs in the treatment and management of multiple myeloma (MM)?
- What are the latest trends and innovations you have observed in the treatment and management of MM leading up to and coming out of ASCO 2024?
- How does relapsed/refractory MM (RRMM), particularly after multiple lines of therapy, affect the quality of life of patients and their families?
Related Videos
Related Content
